JP2025517509A - 脊髄小脳失調症を治療する方法 - Google Patents
脊髄小脳失調症を治療する方法 Download PDFInfo
- Publication number
- JP2025517509A JP2025517509A JP2024569498A JP2024569498A JP2025517509A JP 2025517509 A JP2025517509 A JP 2025517509A JP 2024569498 A JP2024569498 A JP 2024569498A JP 2024569498 A JP2024569498 A JP 2024569498A JP 2025517509 A JP2025517509 A JP 2025517509A
- Authority
- JP
- Japan
- Prior art keywords
- dosage form
- patient
- weeks
- administered
- daily
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263344917P | 2022-05-23 | 2022-05-23 | |
| US63/344,917 | 2022-05-23 | ||
| PCT/US2023/067326 WO2023230451A2 (en) | 2022-05-23 | 2023-05-23 | Methods of treating spinocerebellar ataxias |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025517509A true JP2025517509A (ja) | 2025-06-05 |
| JP2025517509A5 JP2025517509A5 (cg-RX-API-DMAC7.html) | 2026-04-03 |
Family
ID=88920175
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024569498A Pending JP2025517509A (ja) | 2022-05-23 | 2023-05-23 | 脊髄小脳失調症を治療する方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20260124183A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4529485A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2025517509A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20250020409A (cg-RX-API-DMAC7.html) |
| CN (1) | CN120018855A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023230451A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUP2400349A1 (hu) * | 2024-07-05 | 2026-01-28 | Egis Gyógyszergyár Zrt. | Troriluzole-hidroklorid-sók |
| WO2026062600A1 (en) * | 2024-09-22 | 2026-03-26 | Biohaven Therapeutics Ltd. | Troriluzole for use in treating spinocerebellar ataxias |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018154462A2 (en) * | 2017-02-22 | 2018-08-30 | Crispr Therapeutics Ag | Materials and methods for treatment of spinocerebellar ataxia type 2 (sca2) and other spinocerebellar ataxia type 2 protein (atxn2) gene related conditions or disorders |
| PT3706739T (pt) * | 2017-11-12 | 2024-12-04 | Biohaven Therapeutics Ltd | Utilização de profármacos de riluzol para tratar ataxias |
| US20210308111A1 (en) * | 2018-07-27 | 2021-10-07 | With Great Power, Llc | Clinical Methods And Pharmaceutical Compositions Employing AMPA Receptor Antagonists To Treat Glioblastoma And Other Cancers |
| US20230067811A1 (en) * | 2020-01-24 | 2023-03-02 | University Of Virginia Patent Foundation | Modulating lymphatic vessels in neurological disease |
-
2023
- 2023-05-23 JP JP2024569498A patent/JP2025517509A/ja active Pending
- 2023-05-23 US US18/867,416 patent/US20260124183A1/en active Pending
- 2023-05-23 CN CN202380041989.8A patent/CN120018855A/zh active Pending
- 2023-05-23 KR KR1020247038718A patent/KR20250020409A/ko active Pending
- 2023-05-23 WO PCT/US2023/067326 patent/WO2023230451A2/en not_active Ceased
- 2023-05-23 EP EP23812702.1A patent/EP4529485A4/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4529485A2 (en) | 2025-04-02 |
| WO2023230451A3 (en) | 2024-01-04 |
| WO2023230451A2 (en) | 2023-11-30 |
| EP4529485A4 (en) | 2026-05-20 |
| CN120018855A (zh) | 2025-05-16 |
| KR20250020409A (ko) | 2025-02-11 |
| US20260124183A1 (en) | 2026-05-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10537566B2 (en) | Combinations comprising siponimod and laquinimod for the treatment of multiple sclerosis | |
| US20110130466A1 (en) | Use of rasagiline for the treatment of progressive supranuclear palsy | |
| US10285981B2 (en) | Compositions and methods for treating amyotrophic lateral sclerosis in responders | |
| EP4483956B1 (en) | TRORILUZOLE INTENDED FOR USE IN THE TREATMENT OF SPINOCEREBELLOUS ATAXIA 3 (SCA3) | |
| US20260124183A1 (en) | Methods of treating spinocerebellar ataxias | |
| KR20120050512A (ko) | 탈수초를 갖는 환자에서 4-아미노피리딘을 사용한 지속적 치료 | |
| Abelson et al. | Comparative efficacy of olopatadine 0.1% ophthalmic solution versus levocabastine 0.05% ophthalmic suspension using the conjunctival allergen challenge model | |
| WO2026011229A1 (en) | Novel therapy | |
| CA2753754C (en) | Methods for treating schizophrenia | |
| US20250375459A1 (en) | Methods for ameliorating cognitive impairment using bile acid derivatives | |
| WO2026062600A1 (en) | Troriluzole for use in treating spinocerebellar ataxias | |
| WO2023243659A1 (ja) | 線条体ストリオソームのドパミンd1シグナルを標的とした強迫性障害の薬物療法 | |
| CN114984034A (zh) | 一种寡糖类化合物的应用 | |
| HK40033906A (en) | Use of riluzole prodrugs to treat ataxias | |
| HK40033906B (en) | Use of riluzole prodrugs to treat ataxias | |
| Afshinmajd et al. | Comparison the effects of Gabapentin and Propranolol in Patients with essential tremor | |
| EA049071B1 (ru) | Применение пролекарств рилузола для лечения атаксии | |
| HK1160586A (en) | Durable treatment with 4-aminopyridine in patients with demyelination |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20260326 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20260326 |